PolyPid (PYPD) to Release Earnings on Wednesday

PolyPid (NASDAQ:PYPD) is scheduled to post its quarterly earnings results before the market opens on Wednesday, November 13th. Analysts expect PolyPid to post earnings of ($1.07) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

PolyPid (NASDAQ:PYPD) last announced its earnings results on Wednesday, August 14th. The company reported ($1.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.51) by $0.26. On average, analysts expect PolyPid to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

PolyPid Stock Performance

Shares of NASDAQ PYPD opened at $3.54 on Tuesday. The company has a current ratio of 0.95, a quick ratio of 0.95 and a debt-to-equity ratio of 1.95. PolyPid has a 12-month low of $2.95 and a 12-month high of $9.20. The firm has a market capitalization of $16.99 million, a price-to-earnings ratio of -0.35 and a beta of 1.31. The firm has a 50 day moving average of $3.47 and a 200 day moving average of $3.84.

Analysts Set New Price Targets

Several brokerages have weighed in on PYPD. HC Wainwright reaffirmed a “buy” rating and set a $14.00 price target on shares of PolyPid in a report on Wednesday, October 2nd. Craig Hallum assumed coverage on shares of PolyPid in a research note on Monday, November 4th. They set a “buy” rating and a $10.00 price target on the stock.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.